ArticleFrontiers in immunology2025
Preclinical
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Preclinical Evaluation of Novel ConservedVaccines · 2026Article
- High Burden of Sexually Transmitted Infections Among Pre-exposure Prophylaxis (PrEP) Users: Testing and Prevention Needs.AIDS and behavior · 2026Article
- Immunogenicity of a Recombinant Multi-Epitope Vaccine Incorporating GRA14, SAG1, and GRA1 Antigens ofVaccines · 2026Article
- A novel TamA + LtgC bivalent vaccine induces potent immunogenic and bactericidal antibodies against Neisseria gonorrhoeae.Medical microbiology and immunology · 2025Article
- The gonococcal vaccine candidate antigen NGO1701 is a N. gonorrhoeae periplasmic copper storage protein.PLoS pathogens · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Methods: In this study, we expanded the immunological characterization of three targets, NGO0690, NGO0948 and Csp (copper storage protein, previously called NGO1701) to include analysis of their efficacy in a mouse model of gonococcal vaginal infection when combined as a trivalent subunit vaccine and adjuvanted with Alum and MPLA. Results: We reported induction of systemic and mucosal antibody responses, serum bactericidal activity against heterologous Discussion: Overall, our results suggested that the rational design of our multi-antigen subunit vaccines holds translational potential for enhancing broadly protective immune responses and protection against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.